AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9586798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic cases
Number of subjects: 119
Study 9586798 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMD cases
Number of subjects: 119
Study 9586798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older groups
Number of subjects: 119
Study 8109774 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1, 2, 4, and 8 micrograms/kg
Number of subjects: 16
Study 8109774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 1, 2, 4, and 8 micrograms/kg
Number of subjects: 16
Study 3134343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 81
Study 3134343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 30520980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (BRS)
Number of subjects: 262
Study 30520980 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 262
Study 28437263 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO group received oral CHO (400 ml) the prior evening and 2 to 3 hours before surgery.
Number of subjects: 57
Study 28437263 — intervention group
Group type: COMPARATOR
Intervention: Control group was fasted from food and water according to standard protocol.
Number of subjects: 57
Study 25675222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection
Number of subjects: 17
Study 25675222 — intervention group
Group type: COMPARATOR
Intervention: Sterile water injection
Number of subjects: 17
Study 22678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS) with training
Number of subjects: 40
Study 22678947 — intervention group
Group type: COMPARATOR
Intervention: Memory Support System (MSS) without training (Control)
Number of subjects: 40
Study 22678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Care partners of MSS trained individuals
Number of subjects: 40
Study 22678947 — intervention group
Group type: COMPARATOR
Intervention: Care partners of control group
Number of subjects: 40
Study 21212377 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-worn accelerometers (activPAL)
Number of subjects: 46
Study 21212377 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-worn accelerometers (activPAL) on nonaffected leg
Number of subjects: 46
Study 19224088 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (6 percent)
Number of subjects: 40
Study 19224088 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (1.2 percent)
Number of subjects: 40
Study 16828500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-mg pegaptanib continued for 48 weeks (8 injections)
Number of subjects: 1190
Study 16828500 — intervention group
Group type: COMPARATOR
Intervention: Usual care or discontinuation of pegaptanib
Number of subjects: 1190
Study 15342284 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 15342284 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 15342284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 10959738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV)
Number of subjects: 356
Study 10959738 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Number of subjects: 356
Study 9603290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol (N = 9) twice daily for 15 days
Number of subjects: 25
Study 9603290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% bunazosin (N = 10) twice daily for 20 days
Number of subjects: 25
Study 9603290 — intervention group
Group type: COMPARATOR
Intervention: 2.0% carteolol (N = 6)
Number of subjects: 25
Study 9603290 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol (N = 10)
Number of subjects: 25
Study 8256008 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (TNG) - 2 cm of NTG gel administered once a day
Number of subjects: 100
Study 8256008 — intervention group
Group type: COMPARATOR
Intervention: Heparinoid substances - applied three times a day
Number of subjects: 100
Study 3899248 — intervention group
Group type: EXPERIMENTAL
Intervention: Single phenol injection
Number of subjects: 120
Study 3899248 — intervention group
Group type: COMPARATOR
Intervention: Multiple phenol injection
Number of subjects: 120
Study 31888708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral-physical therapy (CBPT) intervention
Number of subjects: 60
Study 31888708 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 29384722 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT in combination with docetaxel 75 mg/m2 for up to six cycles
Number of subjects: 790
Study 29384722 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 790
Study 29384722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy for high-volume disease (n = 513)
Number of subjects: 790
Study 29384722 — intervention group
Group type: COMPARATOR
Intervention: ADT alone for high-volume disease
Number of subjects: 790
Study 29384722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy for low-volume disease (n = 277)
Number of subjects: 790
Study 29384722 — intervention group
Group type: COMPARATOR
Intervention: ADT alone for low-volume disease
Number of subjects: 790
Study 27105868 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg resveratrol
Number of subjects: 36
Study 27105868 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg resveratrol
Number of subjects: 36
Study 27105868 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg resveratrol
Number of subjects: 36
Study 27105868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding before breast-feeding (sequence A)
Number of subjects: 25
Study 24556754 — intervention group
Group type: COMPARATOR
Intervention: Complementary feeding after breast-feeding (sequence B)
Number of subjects: 25
Study 23016710 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Number of subjects: 140
Study 23016710 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 140
Study 20409432 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with standard screening
Number of subjects: 0
Study 20409432 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with proactive screening
Number of subjects: 0
Study 20409432 — intervention group
Group type: COMPARATOR
Intervention: Standard care (brief advice)
Number of subjects: 0
Study 20409432 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (overall)
Number of subjects: 0
Study 18785409 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF hydrogel (100 microg/10 g/100 cm2/d)
Number of subjects: 302
Study 18785409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 15687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional story version
Number of subjects: 0
Study 15687007 — intervention group
Group type: COMPARATOR
Intervention: Neutral story version
Number of subjects: 0
Study 12204985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octylcyanoacrylate, Dermabond)
Number of subjects: 60
Study 12204985 — intervention group
Group type: COMPARATOR
Intervention: Adhesive strips (Steristrips)
Number of subjects: 60
Study 11793153 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physiotherapy
Number of subjects: 148
Study 11793153 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle reconditioning on training devices
Number of subjects: 148
Study 11793153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact aerobics
Number of subjects: 148
Study 11793153 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 148
Study 9625104 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg elemental Ca/d)
Number of subjects: 60
Study 8188467 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated flicker perimeter
Number of subjects: 130
Study 8188467 — intervention group
Group type: COMPARATOR
Intervention: Conventional white/white automated light-sense perimetry
Number of subjects: 130
Study 3671491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium prophylaxis for at least 5 years
Number of subjects: 28
Study 31418151 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 1 g/kg of organic mineral mixture
Number of subjects: 3
Study 31418151 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 0.5 g/kg of organic mineral mixture
Number of subjects: 3
Study 31418151 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + organic mineral mixture (0.5 g/kg and 1 g/kg)
Number of subjects: 3
Study 31418151 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet without organic mineral mixture)
Number of subjects: 3
Study 29519219 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (manikin modified to emulate a morbidly obese patient)
Number of subjects: 101
Study 29519219 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard manikin)
Number of subjects: 101
Study 29519219 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 101
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg (SAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg b.i.d. (MAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 500 mg (MAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat (various doses)
Number of subjects: 68
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat (SAD study)
Number of subjects: 68
Study 28088251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat (MAD study)
Number of subjects: 68
Study 25867075 — intervention group
Group type: EXPERIMENTAL
Intervention: Written asthma action plan
Number of subjects: 407
Study 25867075 — intervention group
Group type: COMPARATOR
Intervention: No written instructions other than prescriptions
Number of subjects: 407
Study 23098249 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to thin body pictures (ET)
Number of subjects: 0
Study 23098249 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to oversized body pictures (EO)
Number of subjects: 0
Study 23098249 — intervention group
Group type: COMPARATOR
Intervention: High avoidance (HA) group
Number of subjects: 0
Study 23098249 — intervention group
Group type: COMPARATOR
Intervention: Low avoidance (LA) group
Number of subjects: 0
Study 21148516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (8 oz of 27% cranberry juice twice daily)
Number of subjects: 319
Study 21148516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 19351303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy Symptom Assessment Scale
Number of subjects: 192
Study 19351303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 192
Study 16816060 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive pregnancy‐tailored telephone counseling
Number of subjects: 442
Study 16816060 — intervention group
Group type: COMPARATOR
Intervention: Best-practice brief counseling
Number of subjects: 442
Study 14643116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (fixed-dose, 36 mg twice daily)
Number of subjects: 3410
Study 14643116 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose, INR 2.0-3.0)
Number of subjects: 3410
Study 14643116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3410
Study 14643116 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3410
Study 10688563 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus care management
Number of subjects: 613
Study 10688563 — intervention group
Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 613
Study 10688563 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 613
Study 9484515 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of sumatriptan subcutaneously
Number of subjects: 52
Study 9484515 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of dihydroergotamine intramuscularly
Number of subjects: 52
Study 7524381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin- and kininogenesis inhibitors (acelysin and kontrykal)
Number of subjects: 0
Study 29996689 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent program
Number of subjects: 743
Study 28265715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40/30 mg
Number of subjects: 1744
Study 28265715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20/15 mg
Number of subjects: 1744
Study 28265715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1744
Study 26710951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca compartment block (FICB) using probe parallel to the inguinal ligament
Number of subjects: 60
Study 26710951 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided fascia iliaca compartment block (FICB) using probe perpendicular to the inguinal ligament
Number of subjects: 60
Study 26710951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Parallel and Perpendicular)
Number of subjects: 60
Study 24206075 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 31
Study 24206075 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 31
Study 21606213 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg, pulmonary capillary wedge pressure > 15 mm Hg, pulmonary vascular resistance > 3 Wood units)
Number of subjects: 242
Study 21606213 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg, pulmonary capillary wedge pressure > 15 mm Hg, pulmonary vascular resistance ≤ Wood units)
Number of subjects: 242
Study 21606213 — intervention group
Group type: COMPARATOR
Intervention: No pulmonary hypertension (mean pulmonary artery pressure ≤ 25 mm Hg)
Number of subjects: 242
Study 19266814 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine and Flunarizine Hydrochloride
Number of subjects: 100
Study 19266814 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 and Flunarizine Hydrochloride
Number of subjects: 100
Study 16783982 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants blaming the victim more if assaulted by a person of the gender they were normally attracted to.
Number of subjects: 161
Study 16783982 — intervention group
Group type: COMPARATOR
Intervention: Female perpetrator
Number of subjects: 161
Study 16783982 — intervention group
Group type: COMPARATOR
Intervention: Male perpetrator
Number of subjects: 161
Study 14568120 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta 1a and/or IFN beta 1b
Number of subjects: 42
Study 10628725 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimuli (CS +) paired with electric stimulus (UCS)
Number of subjects: 35
Study 10628725 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning paradigm with EEG recording
Number of subjects: 35
Study 10628725 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent stimulation (control group)
Number of subjects: 35
Study 8885806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer
Number of subjects: 15
Study 8885806 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 15
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifabutin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg rifabutin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rifabutin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg rifabutin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rifampicin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg rifampicin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 0
Study 1326348 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg isoniazid
Number of subjects: 0
Study 1326348 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0
Study 3885634 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radio- and chemotherapy (group A)
Number of subjects: 44
Study 3885634 — intervention group
Group type: COMPARATOR
Intervention: Combined longterm chemotherapy (group B)
Number of subjects: 44
Study 29197785 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential-oils (EO) mouthwash
Number of subjects: 0
Study 29197785 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study 27992435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 2 times per week for 12 weeks.
Number of subjects: 52
Study 24589881 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg)
Number of subjects: 0
Study 24589881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22538805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 418
Study 20406930 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 58
Study 20406930 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 16705846 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with Schuell's stimulation and psychological care
Number of subjects: 36
Study 16705846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control treatment was)
Number of subjects: 36
Study 15630195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Rice Bran (HRB)
Number of subjects: 50
Study 15630195 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble Rice Bran (RB)
Number of subjects: 50
Study 11381378 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 39
Study 11381378 — intervention group
Group type: COMPARATOR
Intervention: OAA/S scale monitoring (control)
Number of subjects: 39
Study 9232977 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard recruit training program
Number of subjects: 350
Study 9232977 — intervention group
Group type: COMPARATOR
Intervention: Weighted-march activity
Number of subjects: 350
Study 7679415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (not specified in the abstract)
Number of subjects: 985
Study 7679415 — intervention group
Group type: COMPARATOR
Intervention: Nonenrollment
Number of subjects: 985
Study 7679415 — intervention group
Group type: COMPARATOR
Intervention: Dropout
Number of subjects: 985
Study 3120587 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate
Number of subjects: 36
Study 31671938 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles)
Number of subjects: 84
Study 31671938 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy in 30 fractions of 2 Gy)
Number of subjects: 84
Study 31215838 — intervention group
Group type: COMPARATOR
Intervention: SFTSV vaccine
Number of subjects: 0
Study 27974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy stent
Number of subjects: 185
Study 23525552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic humeral centring (DHC)
Number of subjects: 69
Study 23525552 — intervention group
Group type: COMPARATOR
Intervention: Non-specific mobilisation (Control)
Number of subjects: 69
Study 24560483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early IUD insertion 1 week after mifepristone
Number of subjects: 156
Study 24560483 — intervention group
Group type: COMPARATOR
Intervention: Delayed IUD insertion 4‐6 weeks after medical abortion
Number of subjects: 156
Study 24560483 — intervention group
Group type: EXPERIMENTAL
Intervention: Retained IUDs
Number of subjects: 156
Study 21859323 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (baseline) and subgingival debridement (3-month follow-up)
Number of subjects: 134
Study 21859323 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment and supragingival prophylaxis (3-month follow-up)
Number of subjects: 134
Study 21859323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134
Study 19208404 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/day for 4 weeks)
Number of subjects: 32
Study 19208404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19208404 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 32
Study 17389710 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR), 20% CR diet (n = 18)
Number of subjects: 48
Study 17389710 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX), 20% increase in energy expenditure through daily exercise (n = 18)
Number of subjects: 48
Study 17389710 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle guidelines (HL) (n = 10)
Number of subjects: 48
Study 16229115 — intervention group
Group type: EXPERIMENTAL
Intervention: New letrozole preparation
Number of subjects: 25
Study 12145069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Ropivacaine
Number of subjects: 60
Study 12145069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Ropivacaine
Number of subjects: 60
Study 12145069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Bupivacaine
Number of subjects: 60